Polyphenols counteract tumor cell chemoresistance conferred by multidrug resistance proteins

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 880-890

  Michalak, Krystyna ^a   Wesołowska, Olga ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

ABC transporters; Breast cancer resistance protein (BCRP); Flavonoids; MDR modulators; MDR reversal; Multidrug resistance (MDR); Multidrug resistance associated protein 1 (MRP1); P glycoprotein (P gp); Polyphenols; Stilbenes

Indexed keywords

8 PHENYLNARINGENIN; ACACETIN; APIGENIN; AURANTIIN; BAICALEIN; BIOCHANIN A; BREAST CANCER RESISTANCE PROTEIN; CATECHIN; CHRYSIN; DAIDZEIN; EPICATECHIN; EPIGALLOCATECHIN; FISETIN; GALANGIN; GENISTEIN; HESPERETIN; ISOFLAVONE DERIVATIVE; ISOKAEMPFERIDE; KAEMPFEROL; LUTEOLIN; MORIN; MULTIDRUG RESISTANCE PROTEIN 1; MYRICETIN; NARINGENIN; NOBILETIN; POLYPHENOL; QUERCETIN; TANGERETIN; TECTOCHRYSIN; UNINDEXED DRUG;

BINDING AFFINITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESISTANCE; CELL MEMBRANE; CELL MEMBRANE CONDUCTANCE; CELL STRAIN MCF 7; CHEMOSENSITIZATION; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TRANSPORT; ERYTHROCYTE; FRUIT; HUMAN; HUMULUS LUPULUS; HYDROLYSIS; IC 50; IN VITRO STUDY; MOLECULAR MODEL; REVIEW; SILYBUM MARIANUM; STRUCTURE ACTIVITY RELATION; TUMOR CELL; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL PRODUCTS; HUMANS; NEOPLASMS; P-GLYCOPROTEINS; POLYPHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866361427     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650011     Document Type: Review

References (94)

1. Seeger, M.A.; van Veen, H.W. Molecular basis of multidrug transport by ABC transporters. Biochim. Biophys. Acta, 2009, 1794, 725-737.
2. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55, 3-29.
3. Kerr, I.D.; Jones, P.M.; George, A.M. Multidrug efflux pumps: the structures of prokaryotic ATP-binding cassette transporter efflux pumps and implications for our understanding of eukaryotic P-glycoproteins and homologues. Febs J., 2010, 277, 550-563.
4. Zhang, L.; Ma, S. Efflux pump inhibitors: a strategy to combat P-glycoprotein and the NorA multidrug resistance pump. Chem. Med. Chem., 2010, 5, 811-822.
5. Shukla, S.; Wu, C.P.; Ambudkar, S.V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin. Drug Metab. Toxicol., 2008, 4, 205-223.
6. Teodori, E.; Dei, S.; Martelli, C.; Scapecchi, S.; Gualtieri, F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets, 2006, 7, 893-909.
7. Lee, C.H. Reversing agents for ATP-binding cassette drug transporters. Methods Mol. Biol., 2010, 596, 325-340.
8. Ross, J.A.; Kasum, C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 2002, 22, 19-34.
9. Ren, W.; Qiao, Z.; Wang, H.; Zhu, L.; Zhang, L. Flavonoids: promising anticancer agents. Med. Res. Rev., 2003, 23, 519-534.
10. Bansal, T.; Jaggi, M.; Khar, R.K.; Talegaonkar, S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci., 2009, 12, 46-78.
11. Kale, A.; Gawande, S.; Kotwal, S. Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother. Res., 2008, 22, 567-577.
12. Morris, M.E.; Zhang, S. Flavonoid-drug interactions: Effects of flavonoids on ABC transporters. Life Sci., 2006, 78, 2116-2130.
13. Wang, Y.; Cao, J.; Zeng, S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J. Pharm. Pharmacol., 2005, 57, 751-758.
14. Sauna, Z.E.; Smith, M.M.; Mueller, M.; Kerr, K.M.; Ambudkar, S.V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr., 2001, 33, 481-491.
15. Cooray, H.C.; Janvilisri, T.; van Veen, H.W.; Hladky, S.B.; Barrand, M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 2004, 317, 269-275.
16. Lohner, K.; Schnabele, K.; Daniel, H.; Oesterle, D.; Rechkemmer, G.; Gottlicher, M.; Wenzel, U. Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Mol. Nutr. Food Res., 2007, 51, 293-300.
17. Alvarez, A.I.; Real, R.; Perez, M.; Mendoza, G.; Prieto, J.G.; Merino, G. Modulation of the activity of ABC transporters (Pglycoprotein, MRP2, BCRP) by flavonoids and drug response. J. Pharm. Sci., 2010, 99, 598-617.
18. Altenberg, G.A. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr. Med. Chem. Anticancer Agents, 2004, 4, 53-62.
19. Gottesman, M.M.; Ling, V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett., 2006, 580, 998-1009.
20. Ambudkar, S.V.; Kimchi-Sarfaty, C.; Sauna, Z.E.; Gottesman, M.M. P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.
21. Li, Y.; Yuan, H.; Yang, K.; Xu, W.; Tang, W.; Li, X. The structure and functions of P-glycoprotein. Curr. Med. Chem., 2010, 17, 786-800.
22. Scambia, G.; Ranelletti, F.O.; Panici, P.B.; De Vincenzo, R.; Bonanno, G.; Ferrandina, G.; Piantelli, M.; Bussa, S.; Rumi, C.; Cianfriglia, M.; Mancuso, S. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol., 1994, 34, 459-464.
23. Critchfield, J.W.; Welsh, C.J.; Phang, J.M.; Yeh, G.C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem. Pharmacol., 1994, 48, 1437-1445.
24. Kitagawa, S.; Nabekura, T.; Takahashi, T.; Nakamura, Y.; Sakamoto, H.; Tano, H.; Hirai, M.; Tsukahara, G. Structure-activity relationships of the inhibitory effects of flavonoids on Pglycoprotein-mediated transport in KB-C2 cells. Biol. Pharm. Bull., 2005, 28, 2274-2278.
25. Ugocsai, K.; Varga, A.; Molnar, P.; Antus, S.; Molnar, J. Effects of selected flavonoids and carotenoids on drug accumulation and apoptosis induction in multidrug-resistant colon cancer cells expressing MDR1/LRP. In Vivo, 2005, 19, 433-438.
26. Gyemant, N.; Tanaka, M.; Antus, S.; Hohmann, J.; Csuka, O.; Mandoky, L.; Molnar, J. In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. In Vivo, 2005, 19, 367-374.
27. Angelini, A.; Di Ilio, C.; Castellani, M.L.; Conti, P.; Cuccurullo, F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J. Biol. Regul. Homeost. Agents, 2010, 24, 197-205.
28. Limtrakul, P.; Khantamat, O.; Pintha, K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J. Chemother., 2005, 17, 86-95.
29. Zhang, S.; Morris, M.E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 2003, 304, 1258-1267.
30. Zhang, S.; Sagawa, K.; Arnold, R.D.; Tseng, E.; Wang, X.; Morris, M.E. Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. J. Pharm. Sci., 2010, 99, 430-441.
31. Badhan, R.; Penny, J. In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur. J. Med. Chem., 2006, 41, 285-295.
32. Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J.M.; Barron, D.; Di Pietro, A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. USA, 1998, 95, 9831-9836.
33. Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev., 2002, 22, 512-529.
34. Tran, V.H.; Marks, D.; Duke, R.K.; Bebawy, M.; Duke, C.C.; Roufogalis, B.D. Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr. Cancer, 2011, 63, 435-443.
35. Sheu, M.T.; Liou, Y.B.; Kao, Y.H.; Lin, Y.K.; Ho, H.O. A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport. Chem. Pharm. Bull., 2010, 58, 1187-1194.
36. Boumendjel, A.; Bois, F.; Beney, C.; Mariotte, A.M.; Conseil, G.; Di Pietro, A. B-ring substituted 5,7-dihydroxyflavonols with high-affinity binding to P-glycoprotein responsible for cell multidrug resistance. Bioorg. Med. Chem. Lett., 2001, 11, 75-77.
37. Ikegawa, T.; Ohtani, H.; Koyabu, N.; Juichi, M.; Iwase, Y.; Ito, C.; Furukawa, H.; Naito, M.; Tsuruo, T.; Sawada, Y. Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett., 2002, 177, 89-93.
38. Ishii, K.; Tanaka, S.; Kagami, K.; Henmi, K.; Toyoda, H.; Kaise, T.; Hirano, T. Effects of naturally occurring polymethyoxyflavonoids on cell growth, p-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells. Cancer Invest., 2010, 28, 220-229.
39. Choi, C.H.; Kim, J.H.; Kim, S.H. Reversal of P-glycoproteinmediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys. Res. Commun., 2004, 320, 672-679.
40. Takanaga, H.; Ohnishi, A.; Yamada, S.; Matsuo, H.; Morimoto, S.; Shoyama, Y.; Ohtani, H.; Sawada, Y. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J. Pharmacol. Exp. Ther., 2000, 293, 230-236.
41. Vaclavikova, R.; Boumendjel, A.; Ehrlichova, M.; Kovar, J.; Gut, I. Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport? Bioorg. Med. Chem., 2006, 14, 4519-4525.
42. Vaclavikova, R.; Kondrova, E.; Ehrlichova, M.; Boumendjel, A.; Kovar, J.; Stopka, P.; Soucek, P.; Gut, I. The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg. Med. Chem., 2008, 16, 2034-2042.
43. Comte, G.; Daskiewicz, J.B.; Bayet, C.; Conseil, G.; Viornery-Vanier, A.; Dumontet, C.; Di Pietro, A.; Barron, D. C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J. Med. Chem., 2001, 44, 763-768.
44. Di Pietro, A.; Conseil, G.; Perez-Victoria, J.M.; Dayan, G.; Baubichon-Cortay, H.; Trompier, D.; Steinfels, E.; Jault, J.M.; de Wet, H.; Maitrejean, M.; Comte, G.; Boumendjel, A.; Mariotte, A.M.; Dumontet, C.; McIntosh, D.B.; Goffeau, A.; Castanys, S.; Gamarro, F.; Barron, D. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell. Mol. Life Sci., 2002, 59, 307-322.
45. Wesolowska, O.; Wisniewski, J.; Sroda, K.; Krawczenko, A.; Bielawska-Pohl, A.; Paprocka, M.; Dus, D.; Michalak, K. 8Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur. J. Pharmacol., 2010, 644, 32-40.
46. Lee, S.H.; Kim, H.J.; Lee, J.S.; Lee, I.S.; Kang, B.Y. Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol from hops. Arch. Pharm. Res., 2007, 30, 1435-1439.
47. Maitrejean, M.; Comte, G.; Barron, D.; El Kirat, K.; Conseil, G.; Di Pietro, A. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg. Med. Chem. Lett., 2000, 10, 157-160.
48. Chan, K.F.; Zhao, Y.; Chow, T.W.; Yan, C.S.; Ma, D.L.; Burkett, B.A.; Wong, I.L.; Chow, L.M.; Chan, T.H. Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships. Chem. Med. Chem., 2009, 4, 594-614.
49. Jaganathan, S.K. Can flavonoids from honey alter multidrug resistance? Med. Hypotheses, 2011, 76, 535-537.
50. Mei, Y.; Qian, F.; Wei, D.; Liu, J. Reversal of cancer multidrug resistance by green tea polyphenols. J. Pharm. Pharmacol., 2004, 56, 1307-1314.
51. Jodoin, J.; Demeule, M.; Beliveau, R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta, 2002, 1542, 149-159.
52. König, J.; Nies, A.T.; Cui, Y.; Leier, I.; Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta, 1999, 1461, 377-394.
53. Boumendjel, A.; Baubichon-Cortay, H.; Trompier, D.; Perrotton, T.; Di Pietro, A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev., 2005, 25, 453-472.
54. He, S.M.; Li, R.; Kanwar, J.R.; Zhou, S.F. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ ABCC1). Curr. Med. Chem., 2011, 18, 439-481.
55. Trompier, D.; Baubichon-Cortay, H.; Chang, X.B.; Maitrejean, M.; Barron, D.; Riordon, J.R.; Di Pietro, A. Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell. Mol. Life. Sci., 2003, 60, 2164-2177.
56. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab. Dispos., 2003, 31, 11-15.
57. Leslie, E.M.; Mao, Q.; Oleschuk, C.J.; Deeley, R.G.; Cole, S.P.C. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol., 2001, 59, 1171-1180.
58. van Zanden, J.J.; Geraets, L.; Wortelboer, H.M.; van Bladeren, P.J.; Rietjens, I.M.; Cnubben, N.H. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem. Pharmacol., 2004, 67, 1607-1617.
59. van Zanden, J.J.; de Mul, A.; Wortelboer, H.M.; Usta, M.; van Bladeren, P.J.; Rietjens, I.M.; Cnubben, N.H. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem. Pharmacol., 2005, 69, 1657-1665.
60. Wu, C.P.; Calcagno, A.M.; Hladky, S.B.; Ambudkar, S.V.; Barrand, M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). Febs J., 2005, 272, 4725-4740.
61. Lania-Pietrzak, B.; Michalak, K.; Hendrich, A.B.; Mosiadz, D.; Grynkiewicz, G.; Motohashi, N.; Shirataki, Y. Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. Life Sci., 2005, 77, 1879-1891.
62. Rychlik, B.; Balcerczyk, A.; Klimczak, A.; Bartosz, G. The role of multidrug resistance protein 1 (MRP1) in transport of fluorescent anions across the human erythrocyte membrane. J. Membr. Biol., 2003, 193, 79-90.
63. Bobrowska-Hagerstrand, M.; Wrobel, A.; Mrowczynska, L.; Soderstrom, T.; Shirataki, Y.; Motohashi, N.; Molnar, J.; Michalak, K.; Hagerstrand, H. Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. Oncol. Res., 2003, 13, 463-469.
64. Wesolowska, O.; Hendrich, A.B.; Lania-Pietrzak, B.; Wisniewski, J.; Molnar, J.; Ocsovszki, I.; Michalak, K. Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids. Cell. Mol. Biol. Lett., 2009, 14, 199-221.
65. Lania-Pietrzak, B.; Hendrich, A.B.; Zugaj, J.; Michalak, K. Metabolic O-demethylation does not alter the influence of isoflavones on the biophysical properties of membranes and MRP1-like protein transport activity. Arch. Biochem. Biophys., 2005, 433, 428-434.
66. Wesolowska, O.; Wisniewski, J.; Duarte, N.; Ferreira, M.J.; Michalak, K. Inhibition of MRP1 transport activity by phenolic and terpenic compounds isolated from Euphorbia species. Anticancer Res., 2007, 27, 4127-4133.
67. Pick, A.; Muller, H.; Mayer, R.; Haenisch, B.; Pajeva, I.K.; Weigt, M.; Bonisch, H.; Muller, C.E.; Wiese, M. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg. Med. Chem., 2011, 19, 2090-2102.
68. Tamaki, H.; Satoh, H.; Hori, S.; Ohtani, H.; Sawada, Y. Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab. Pharmacokinet., 2010, 25, 170-179.
69. Robey, R.W.; To, K.K.; Polgar, O.; Dohse, M.; Fetsch, P.; Dean, M.; Bates, S.E. ABCG2: a perspective. Adv. Drug Deliv. Rev., 2009, 61, 3-13.
70. Doyle, L.A.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22, 7340-7358.
71. Sugimoto, Y.; Tsukahara, S.; Ishikawa, E.; Mitsuhashi, J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci., 2005, 96, 457-465.
72. Zhang, S.; Yang, X.; Morris, M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol., 2004, 65, 1208-1216.
73. Noguchi, K.; Katayama, K.; Mitsuhashi, J.; Sugimoto, Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev., 2009, 61, 26-33.
74. Polgar, O.; Robey, R.W.; Bates, S.E. ABCG2: structure, function and role in drug response. Expert Opin. Drug Metab. Toxicol., 2008, 4, 1-15.
75. Nicolle, E.; Boumendjel, A.; Macalou, S.; Genoux, E.; Ahmed-Belkacem, A.; Carrupt, P.A.; Di Pietro, A. QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv. Drug Deliv. Rev., 2009, 61, 34-46.
76. Zhang, S.; Yang, X.; Morris, M.E. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res., 2004, 21, 1263-1273.
77. An, G.; Morris, M.E. Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro. Pharm. Res., 2010, 27, 1296-1308.
78. Ahmed-Belkacem, A.; Pozza, A.; Munoz-Martinez, F.; Bates, S.E.; Castanys, S.; Gamarro, F.; Di Pietro, A.; Perez-Victoria, J.M. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res., 2005, 65, 4852-4860.
79. Katayama, K.; Masuyama, K.; Yoshioka, S.; Hasegawa, H.; Mitsuhashi, J.; Sugimoto, Y. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother. Pharmacol., 2007, 60, 789-797.
80. Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Roberti, M.; Pizzirani, D.; Meli, M.; Dusonchet, L.; Gebbia, N.; Abbadessa, V.; Crosta, L.; Barucchello, R.; Grisolia, G.; Invidiata, F.; Simoni, D. Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int. J. Biochem. Cell. Biol., 2005, 37, 1709-1726.
81. Ferreira, M.J.; Duarte, N.; Gyemant, N.; Radics, R.; Cherepnev, G.; Varga, A.; Molnar, J. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res., 2006, 26, 3541-3546.
82. Wesolowska, O.; Wisniewski, J.; Bielawska-Pohl, A.; Paprocka, M.; Duarte, N.; Ferreira, M.J.; Dus, D.; Michalak, K. Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells. Anticancer Res., 2010, 30, 4587-4593.
83. Bobrowska-Hagerstrand, M.; Lillas, M.; Mrowczynska, L.; Wrobel, A.; Shirataki, Y.; Motohashi, N.; Hagerstrand, H. Resveratrol oligomers are potent MRP1 transport inhibitors. Anticancer Res., 2006, 26, 2081-2084.
84. Kweon, S.H.; Song, J.H.; Kim, T.S. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem. Biophys. Res. Commun., 2010, 395, 104-110.
85. Quan, F.; Zhang, S.Q.; Bai, Y.X.; Yao, X.B.; Li, H.H.; Yu, L.; Pan, C.E. Resveratrol increases sensitivity of CNE2 cells to chemotherapeutic drugs under hypoxia. Zhong Xi Yi Jie He Xue Bao, 2009, 7, 952-957.
86. Valdameri, G.; Pereira Rangel, L.; Spatafora, C.; Guitton, J.; Gauthier, C.; Arnaud, O.; Ferreira-Pereira, A.; Falson, P.; Winnischofer, S.M.; Rocha, M.E.; Tringali, C.; Pietro, A.D. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein. ACS Chem. Biol., 2012, 7, 322-330.
87. Alfaras, I.; Perez, M.; Juan, M.E.; Merino, G.; Prieto, J.G.; Planas, J.M.; Alvarez, A.I. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J. Agric. Food Chem., 2010, 58, 4523-4528.
88. van de Wetering, K.; Burkon, A.; Feddema, W.; Bot, A.; de Jonge, H.; Somoza, V.; Borst, P. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol., 2009, 75, 876-885.
89. Juan, M.E.; Gonzalez-Pons, E.; Planas, J.M. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr., 2010, 140, 489-495.
90. Ebert, B.; Seidel, A.; Lampen, A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol. Sci., 2007, 96, 227-236.
91. Jonker, J.W.; Smit, J.W.; Brinkhuis, R.F.; Maliepaard, M.; Beijnen, J.H.; Schellens, J.H.; Schinkel, A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 2000, 92, 1651-1656.
92. Brand, W.; Schutte, M.E.; Williamson, G.; van Zanden, J.J.; Cnubben, N.H.; Groten, J.P.; van Bladeren, P.J.; Rietjens, I.M. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed. Pharmacother., 2006, 60, 508-519.
93. Tian, R.; Koyabu, N.; Takanaga, H.; Matsuo, H.; Ohtani, H.; Sawada, Y. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm. Res., 2002, 19, 802-809.
94. Spahn-Langguth, H.; Langguth, P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur.J. Pharm. Sci., 2001, 12, 361-367.